Investigating Pleckstrin-2's role in myeloid cell growth
The role of Pleckstrin-2 as a functional node in myeloid proliferation
This study is looking at how a protein called Pleckstrin-2 affects myeloproliferative neoplasms (MPNs) in patients with a specific mutation, and it aims to find new treatments that could work better for you if current therapies aren't helping.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10650349 on NIH RePORTER |
What this research studies
This research focuses on myeloproliferative neoplasms (MPNs), which are bone marrow diseases characterized by excessive production of myeloid cells. The study aims to understand how Pleckstrin-2, a protein involved in cell signaling, affects the development of these diseases, particularly in patients with the JAK2V617F mutation. Researchers are exploring new treatment options by developing small molecule inhibitors targeting Pleckstrin-2, which may help overcome resistance to current therapies. By using advanced screening techniques, they hope to identify effective compounds that can improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with myeloproliferative neoplasms, particularly those with the JAK2V617F mutation.
Not a fit: Patients with myeloproliferative neoplasms who do not have the JAK2V617F mutation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for myeloproliferative neoplasms that are more effective and have fewer side effects than current therapies.
How similar studies have performed: Previous research has shown promise in targeting the JAK2 pathway for treating myeloproliferative neoplasms, but the specific approach of targeting Pleckstrin-2 is novel.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Ji, Peng — Northwestern University at Chicago
- Study coordinator: Ji, Peng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.